CA2911947A1 - Compositions comprising a mixture of bacteria comprising pedoiococcus and lactobacillus and methods for decreasing the effects of alcohols - Google Patents

Compositions comprising a mixture of bacteria comprising pedoiococcus and lactobacillus and methods for decreasing the effects of alcohols

Info

Publication number
CA2911947A1
CA2911947A1 CA2911947A CA2911947A CA2911947A1 CA 2911947 A1 CA2911947 A1 CA 2911947A1 CA 2911947 A CA2911947 A CA 2911947A CA 2911947 A CA2911947 A CA 2911947A CA 2911947 A1 CA2911947 A1 CA 2911947A1
Authority
CA
Canada
Prior art keywords
bacteria
composition
mixture
formulation
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2911947A
Other languages
English (en)
French (fr)
Inventor
Richard Carpenter
Amit Kapur
Narayan Suresh
E. Wesley Huff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biowish Technologies Inc
Original Assignee
Biowish Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biowish Technologies Inc filed Critical Biowish Technologies Inc
Publication of CA2911947A1 publication Critical patent/CA2911947A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Jellies, Jams, And Syrups (AREA)
CA2911947A 2013-05-10 2014-05-12 Compositions comprising a mixture of bacteria comprising pedoiococcus and lactobacillus and methods for decreasing the effects of alcohols Abandoned CA2911947A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361821974P 2013-05-10 2013-05-10
US61/821,974 2013-05-10
PCT/US2014/037704 WO2014183117A1 (en) 2013-05-10 2014-05-12 Compositions comprising a mixture of bacteria comprising pedoiococcus and lactobacillus an methods for decreasing the effects of alcohols

Publications (1)

Publication Number Publication Date
CA2911947A1 true CA2911947A1 (en) 2014-11-13

Family

ID=50980375

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2911947A Abandoned CA2911947A1 (en) 2013-05-10 2014-05-12 Compositions comprising a mixture of bacteria comprising pedoiococcus and lactobacillus and methods for decreasing the effects of alcohols

Country Status (10)

Country Link
US (1) US10130664B2 (cg-RX-API-DMAC7.html)
EP (1) EP2994149A1 (cg-RX-API-DMAC7.html)
JP (1) JP6452258B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160013069A (cg-RX-API-DMAC7.html)
CN (1) CN106456679A (cg-RX-API-DMAC7.html)
AU (2) AU2014262427B2 (cg-RX-API-DMAC7.html)
CA (1) CA2911947A1 (cg-RX-API-DMAC7.html)
HK (1) HK1222584A1 (cg-RX-API-DMAC7.html)
RU (1) RU2671221C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014183117A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170005093A (ko) 2014-05-12 2017-01-11 바이오위시 테크놀로지스, 인크. 인간 건강 및 영양 향상을 위한 조성물 및 방법
KR101853603B1 (ko) * 2017-05-18 2018-05-02 주식회사 쎌바이오텍 알코올 또는 아세트알데하이드 분해용 프로바이오틱스를 포함하는 조성물
WO2019232026A1 (en) 2018-05-29 2019-12-05 BiOWiSH Technologies, Inc. Compositions and methods for improving survivability of aquatic animals
CN109350629B (zh) * 2018-08-09 2021-06-01 新乡医学院 一种用于治疗酒精戒断综合征的益生菌复合制剂及其制备方法
CN115919907A (zh) * 2021-08-31 2023-04-07 E·施约林 一种用于治疗和/或预防食物和/或酒精中毒的组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007867A2 (en) * 1996-08-22 1998-02-26 Bioteknologisk Institut Metabolically engineered lactic acid bacteria and means for providing same
US6953574B2 (en) * 2002-06-21 2005-10-11 Technology Commercialization, Inc. Method for producing a fermented hydrolyzed medium containing microorganisms
CN1993052B (zh) * 2004-07-29 2011-08-17 京都府 植物病害防除剂和防除方法
FR2881751B1 (fr) * 2005-02-07 2007-04-27 Virbac Sa Sa Compositions comprenant des micro-organismes deshydrates, leurs procedes de preparation, et leurs utilisations
KR100661032B1 (ko) * 2005-04-19 2006-12-22 주식회사한국야쿠르트 간 기능 개선, 혈중 알코올 감소 및 항산화에 유효한조성물
US20060263385A1 (en) 2005-05-17 2006-11-23 Fran Gare Composition to relieve side effects of alcohol intoxication
JP5413819B2 (ja) * 2008-02-08 2014-02-12 国立大学法人広島大学 肝機能改善剤およびその製造用ツール、ならびにこれらの利用
IT1392101B1 (it) 2008-12-12 2012-02-09 Zuccari Societa A Responsabilita Limitata In Breve Zuccari S R L Composizione comprendente isoflavoni
US9579353B2 (en) * 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
US9161957B2 (en) 2012-08-03 2015-10-20 Life Well Lived, Llc Compositions and methods for reducing blood alcohol content
CN104755092A (zh) * 2012-10-30 2015-07-01 雀巢产品技术援助有限公司 用于递送协同免疫作用的包含微粒和益生菌的组合物
CN102934809B (zh) * 2012-12-10 2014-04-30 济南大学 益生菌发酵中药制剂制备的组合物及其制备方法和应用

Also Published As

Publication number Publication date
US10130664B2 (en) 2018-11-20
CN106456679A (zh) 2017-02-22
EP2994149A1 (en) 2016-03-16
AU2014262427B2 (en) 2018-12-13
AU2014262427A1 (en) 2015-11-26
AU2019201637A1 (en) 2019-04-11
RU2015152826A (ru) 2017-06-20
RU2671221C2 (ru) 2018-10-30
JP2016521287A (ja) 2016-07-21
KR20160013069A (ko) 2016-02-03
HK1222584A1 (zh) 2017-07-07
JP6452258B2 (ja) 2019-01-16
US20140335187A1 (en) 2014-11-13
WO2014183117A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
AU2013338774B2 (en) Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
AU2019201637A1 (en) Compositions Comprising a Mixture of Bacteria Comprising Pediococcus and Lactobacillus and Methods for Decreasing the Effects of Alcohols
JP2019516775A (ja) プロバイオティクス及び消化酵素の組成物並びにその調製方法及び使用
WO1997035596A1 (en) Method and formula for the prevention of diarrhea
KR20180081170A (ko) 당을 전혀 또는 거의 함유하지 않은 안정한 건조 조성물
US11045509B2 (en) Tributyrin compositions and methods therefor
WO2014068338A1 (en) Diverticulitis treatment
AU2011314299B2 (en) Compositions and methods for augmenting kidney function
JP5592640B2 (ja) 乳酸菌発酵ローヤルゼリーを含有する抗ストレス剤、その製造方法、視床下部−下垂体−副腎皮質系の活動抑制剤、及び交感神経−副腎髄質系の活動抑制剤
JP2002522393A (ja) 共生乳酸産生細菌を使用する、栄養材料の溶解度を増大するための方法
JP2016521287A6 (ja) ペディオコッカス（Ｐｅｄｉｏｃｏｃｃｕｓ）とラクトバチルス（Ｌａｃｔｏｂａｃｉｌｌｕｓ）とを含む細菌の混合物を含む組成物、ならびにアルコールの影響を軽減するための方法
JP2005013211A (ja) 乳酸菌含有食品組成物
TWI861750B (zh) 提升睡眠品質之益生菌組成物及其用途
TW202602432A (zh) 合生元用於製備提升類升糖素胜肽-1的組合物的用途
JP2026008765A (ja) シンバイオティクスの、グルカゴン様ペプチド－１を上昇させる組成物の調製における用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190329

FZDE Discontinued

Effective date: 20210831